In vitro and in silico evaluations reveal that structural changes in β-nitrostyrene affect its toxicity profiles.
Abstract β-Nitrostyrene, an important intermediate in chemical industry, shows relevant anti-proliferative and pro-apoptotic potential and has thus been suggested for potential use in tumor chemotherapy. If not derivatized, β-nitrostyrene is however, highly reactive and possess (geno)toxic potential. To decipher structural elements relevant for biological activity, crucial for both, chemical risk assessment and potential drug development, a panel of nine structural derivatives of β-nitrostyrene, was put together. It included structures with and without nitrovinyl moiety and was based on fingerprint similarity, QSAR-based mutagenicity alerts, and literature reports. It comprised simple structures like styrene and more complex structures such as 2-methoxy-5-[(E)-2-nitroethenyl]phenol. In vitro experiments in human WS1 and mouse L5178/TK ± cells demonstrated that the nitrovinyl moiety of β-nitrostyrene seems vital for its cytotoxic (membrane damage, metabolic competence) and genotoxic (clastogenicity, mutagenicity) properties. The extent of adversity varied with modification of structural elements. For example 1-nitro-2-[(E)-2-nitroethenyl]benzene led to 2.3-fold higher mean tail intensities in the alkaline comet assay than β-nitrostyrene. Notably, all derivatives with a nitrovinyl moiety, except 5-[(E)-2-nitroethenyl]-1,3-benzodioxole, induced DNA double-strand breaks, as judged by γH2A.X induction. In conclusion, our study identified structural elements responsible for the cyto- and genotoxic potential of β-nitrostyrene, demonstrating that minor structural changes can significantly alter its adverse biological activity.
No takes yet. Share an insight, caveat, or question.
Sündermann et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: